Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.

Soon Ki Kim Ki Young Yoo Kun Soo Lee Tai Ju Hwang Yong Mook Choi Eun Jin Choi Sang Kyu Park

Published in: Journal of Korean medical science (2018)

The results of this PMS study support the use of GreenGene F™ as safe and efficacious in hemorrhage prevention and treatment of hemophilia A. These results are consistent with the findings from previously published GreenGene F™ studies.

Keyphrases

public health
randomized controlled trial
data analysis
replacement therapy